Subscribe to our Newsletters !!
Although copying the blueprint is extremely comple
Eppendorf introduces a new addition to their Eppen
The recent rabies death of an 11 year old Canadian
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micro
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator’s nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.
Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.
This is the first of its kind COVID-19 jab to undergo human clinical trials in India.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
